Seven Green Lights From EU’s CHMP, Including Drugs For Hemophilia, Diabetes, Alpha Mannosidosis And Hyperkalemia

The European Medicines Agency’s CHMP has OKd seven new products, including drugs for hemophilia A, diabetes, alpha mannosidosis, hyperkalemia and herpes zoster. But it again rejected Santhera’s filing for Raxone in the new indication of Duchenne muscular dystrophy, and also turned down Repros’ Encyzix for hypogonadism.

Thumbs up
The EU's CHMP OKd seven new products this week.

The European Medicines Agency’s key scientific committee, the CHMP, this week recommended approval of seven products, the same number as in December 2017. They include Roche’s Hemlibra (emicizumab) for hemophilia A, Chiesi Farmaceutici’s orphan drug Lamzede (velmanase alfa) for alpha mannosidosis, and GlaxoSmithKline PLC’s Shingrix, a vaccine for herpes zoster.

At its first monthly meeting of 2018, the CHMP also confirmed its earlier positive opinion on AstraZeneca PLC’s Lokelma...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>